BPTF is overexpressed in NSCLC and is associated with poor prognosis [134,135], and as cisplatin is a mainstay of NSCLC therapy, it will be important moving forward to determine if expression of either NSUN2 or BTPF is associated with resistance to cisplatin. The gene discussed is NSUN2; the disease is non-small cell lung carcinoma.